Blood purification therapies in methotrexate-induced acute kidney injury: Four case reports

4Citations
Citations of this article
10Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Methotrexate (MTX), a folic acid antimetabolite, is administered at a high dose for the treatment of diseases such as leukemia and malignant lymphoma. Often, an effort is made to reduce the adverse effects of MTX by monitoring MTX concentration in the blood and administering a high dose of leucovorin. However, side effects of MTX are still reported. MTX is metabolized in the liver and eliminated via the kidneys; hence, blood purification therapy is useful for the reduction of MTX blood concentration in case of renal impairment. Case presentation: We performed various types of blood purification therapies in four cases of MTX poisoning that accompanied renal impairment. Conclusions: Based on our results, we concluded that hemodialysis or hemoperfusion with an activated carbon absorption column was useful for the elimination of MTX from the blood. It is important to choose an appropriate blood purification method understanding the characteristics of each blood purification method.

Cite

CITATION STYLE

APA

Fujikura, E., Akiu, M., Miyauchi, K., Yoshida, M., Aoki, S., Yamamoto, T., … Ito, S. (2017). Blood purification therapies in methotrexate-induced acute kidney injury: Four case reports. Renal Replacement Therapy, 3(1). https://doi.org/10.1186/s41100-017-0129-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free